[ad_1]
ReNeuron Group PLC (LON: RENE) said that its cell-based treatment had shown signs that it could improve the vision of people suffering from a disease that causes blindness. US researchers are conducting a Phase I / II clinical study of people with retinitis pigmentosa. ReNeuron's Chief Financial Officer, Michael Hunt, tells Proactive London why these early data are so encouraging after three patients from one group in Phase II of the study were treated. The doctors used human retinal progenitor cells developed by the Life Sciences Society, listed in the AIM. Preclinical studies have shown that they can preserve existing photoreceptors in the retina, which could reduce or stop the deterioration of vision. In addition, it has been shown that these progenitor cells become functional photoreceptors that could then help restore vision. The trial's lead investigator was Jason Comander of the Mbadachusetts Eye and Ear, also an adjunct professor at Harvard Medical School.
"It is exciting to enter a patient population whose remaining vision and remaining architecture support the possibility of visual improvement and I am very much looking forward to obtaining additional results from this cohort." of patients and the next one. "
Source link
